Insilico Medicine Advances AI-Driven Drug Rentosertib into Phase III Trial for IPF — Insilico Medicine Inc.

Event summary

Insilico Medicine dosed the first patient in the Phase III trial (GENESIS-IPF-3) for Rentosertib, an AI-driven drug for idiopathic pulmonary fibrosis (IPF).
The trial, led by Professor Zuojun Xu, will enroll 320 participants across 47 centers in China, with primary endpoints focusing on lung function decline.
Rentosertib, targeting TNIK, is the first drug candidate discovered and developed using generative AI, advancing to Phase III after promising Phase IIa results.
Insilico reported $106 million in revenue for H1 2026, a 287% YoY increase, driven by collaborations with global partners, including Eli Lilly and Takeda.
The company nominated nine development candidates within nine months of 2026, setting a new record for annual pipeline productivity.

The big picture

Insilico Medicine's advancement of Rentosertib into Phase III marks a significant milestone in AI-driven drug discovery, potentially redefining target identification for complex diseases. The company's strategic collaborations and revenue growth underscore its viability as a sustainable commercial model in the biotech sector. The success of Rentosertib could validate the efficacy of generative AI in accelerating drug development, setting a precedent for future innovations in the field.

What we're watching

Clinical Validation: Whether Rentosertib can achieve primary endpoints in the Phase III trial, validating its efficacy in a larger patient population over a longer treatment period.
Regulatory Approval: The pace at which Rentosertib progresses from Phase III initiation to final regulatory approval, with a timeline of three to four years under favorable conditions.
Commercial Strategy: How Insilico's dual-purpose therapeutic strategy and out-licensing collaborations will sustain its revenue growth and profitability.